Abstract
Although significant advances have been made in the treatment of breast cancer using chemotherapy, less than half of the patients treated for localized breast cancer benefit from adjuvant chemotherapy and most patients with metastatic cancer eventually develop disease that is chemotherapy resistant. Targeted agents, such as inhibitors of tyrosine kinases, offer the opportunity to reverse chemotherapy resistance and enhance response in patients with localized and advanced breast cancer. Such combined approaches have been established for the treatment of advanced breast cancer and are now demonstrating benefit in the adjuvant arena. This review summarizes the results of several trials involving the use of tyrosine kinase inhibition in combination with chemotherapy for the treatment of breast cancer and discusses future directions for breast cancer biotherapy.
Keywords: Breast cancer, Biotherapy, Tyrosine kinase, Targeted therapy, Lapatinib, Trastuzumab, Bevacizumab
Anti-Cancer Agents in Medicinal Chemistry
Title: Inhibition of Receptor Tyrosine Kinases in Combination with Chemotherapy for the Treatment of Breast Cancer
Volume: 8 Issue: 5
Author(s): S. L. Moulder, B. S. Craft and G. N. Hortobagyi
Affiliation:
Keywords: Breast cancer, Biotherapy, Tyrosine kinase, Targeted therapy, Lapatinib, Trastuzumab, Bevacizumab
Abstract: Although significant advances have been made in the treatment of breast cancer using chemotherapy, less than half of the patients treated for localized breast cancer benefit from adjuvant chemotherapy and most patients with metastatic cancer eventually develop disease that is chemotherapy resistant. Targeted agents, such as inhibitors of tyrosine kinases, offer the opportunity to reverse chemotherapy resistance and enhance response in patients with localized and advanced breast cancer. Such combined approaches have been established for the treatment of advanced breast cancer and are now demonstrating benefit in the adjuvant arena. This review summarizes the results of several trials involving the use of tyrosine kinase inhibition in combination with chemotherapy for the treatment of breast cancer and discusses future directions for breast cancer biotherapy.
Export Options
About this article
Cite this article as:
Moulder L. S., Craft S. B. and Hortobagyi N. G., Inhibition of Receptor Tyrosine Kinases in Combination with Chemotherapy for the Treatment of Breast Cancer, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (5) . https://dx.doi.org/10.2174/187152008784533080
DOI https://dx.doi.org/10.2174/187152008784533080 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Generation of a Chimeric Plasmin-resistant VEGF165/VEGF183 (132-158) Protein and its Comparative Activity
Protein & Peptide Letters The Extra-Hematopoietic Role of Erythropoietin in Diabetes Mellitus
Current Diabetes Reviews Anti-Tumor Mechanisms of Novel 3-(4-Substituted Benzyl)-5-Isopropil-5- Phenylhydantoin Derivatives in Human Colon Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry Pomegranate Extract, A Prooxidant with Antiproliferative and Proapoptotic Activities Preferentially Towards Carcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry Modified Nucleosides That Can Be Incorporated into DNA Enzymatically or in Live Cells
Current Organic Chemistry Natural Endoperoxides as Drug Lead Compounds
Current Medicinal Chemistry Mesenchymal Cells in the Treatment of Spinal Cord Injury: Current & Future Perspectives
Current Stem Cell Research & Therapy NF-κB Down–regulation and PARP Cleavage by novel 3-α-butyryloxy-β-boswellic Acid Results in Cancer Cell Specific Apoptosis and in vivo Tumor Regression
Anti-Cancer Agents in Medicinal Chemistry MiR-147: Functions and Implications in Inflammation and Diseases
MicroRNA An Overview on 2-arylquinolin-4(1H)-ones and Related Structures as Tubulin Polymerisation Inhibitors
Current Topics in Medicinal Chemistry Applications of Lipid based Formulation Technologies in the Delivery of Biotechnology-based Therapeutics
Current Pharmaceutical Biotechnology Recent Advances in the New Generation Taxane Anticancer Agents
Medicinal Chemistry Newly Identified Tumor Antigens as Promising Cancer Vaccine Targets for Malignant Melanoma Treatment
Current Topics in Medicinal Chemistry Multifunctional Materials for Cancer Therapy: From Antitumoral Agents to Innovative Administration
Current Organic Chemistry Carotenoids as Modulators of Intracellular Signaling Pathways
Current Signal Transduction Therapy Marine Drugs: A Hidden Wealth and a New Epoch for Cancer Management
Current Drug Metabolism Anaemia in Diabetes: An Emerging Complication of Microvascular Disease
Current Diabetes Reviews An Introduction to the Nutrition and Metabolism of Choline
Central Nervous System Agents in Medicinal Chemistry Imaging of Hypoxia Using PET and MRI
Current Pharmaceutical Biotechnology Selection Criteria for Probiotics and Potential of Cereal Based Food Products as Novel Probiotic-Carriers
Current Nutrition & Food Science